Arcutis Biotherapeutics (ARQT) drew investor attention after reporting third quarter 2026 earnings, with net product revenue for ZORYVE up 45% year over year and full year sales guidance nudged higher. The reaction in Arcutis Biotherapeutics’ share price has been sharp, with the stock falling about 20.7% on the day and 15.8% over the past week. This comes even though the 30 day share price return is up 11.7% and the 1 year total shareholder return sits at 11.4%. The very large 3 year total...
Arcutis Biotherapeutics (ARQT) stock plunges as the company's Q3 2026 earnings falls short of forecasts amid higher costs. Read more here.
What the new ZORYVE data means for Arcutis Biotherapeutics stock Arcutis Biotherapeutics (ARQT) just used two major dermatology conferences to showcase fresh clinical and real world data across its ZORYVE portfolio, putting the product suite, not macro headlines, at the center of the stock story. Investors now have more detail on how ZORYVE cream and foam are being studied across atopic dermatitis, plaque psoriasis and seborrheic dermatitis, as well as new research on long term topical...
Arcutis Biotherapeutics' fair value is estimated at $24.41 per share, with upside contingent on clinical wins. Read why ARQT stock is downgraded to a hold.
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Key TakeawaysConference Pop: Arcutis Biotherapeutics stock jumped 11. 19% on September 16, closing at $26.
Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.
Arcutis Biotherapeutics Stock Performance Snapshot Arcutis Biotherapeutics (ARQT) has drawn investor attention after recent share price moves, with the stock down about 12% over the past month but up roughly 16% over the past 3 months. The company, which focuses on dermatological treatments such as its lead product ZORYVE, now carries a market value of about US$3.16b and recently closed at US$24.87 as of 25 August 2026. Looking at the bigger picture, Arcutis Biotherapeutics has seen mixed...
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
This is the newest page. Registered accounts read further back.